New York, May 22, 2026, 12:05 (EDT)
Caribou Biosciences shares edged higher on Friday, holding near $2 as investors looked past a quiet news tape and toward cancer-drug updates due next month.
The stock recently traded at $2.01, up about 1% from Thursday’s close of $1.99, after moving between $1.972 and $2.040. The company’s market value was about $198 million, Investing.com data showed.
The timing matters. Trading comes before a three-day U.S. market weekend, with Nasdaq’s 2026 calendar listing Memorial Day, May 25, as a closed session for U.S. equity and options markets.
For Caribou, the next real test is not Friday’s tape. It is data. The company said on May 12 that two abstracts were accepted for oral presentations at the European Hematology Association meeting in Stockholm in June, covering vispa-cel and CB-011, its two main off-the-shelf cancer cell therapy programs.
CAR-T, or chimeric antigen receptor T-cell therapy, is a cancer treatment that engineers immune cells to attack tumors. Caribou’s pitch is allogeneic CAR-T — donor-derived cells meant to be available “off the shelf,” rather than made from each patient’s own cells.
Earlier this month, Chief Executive Rachel Haurwitz said Caribou had “aligned with the FDA on the pivotal ANTLER-3 trial design” for vispa-cel. The planned trial is expected to enroll about 250 second-line large B-cell lymphoma patients who are not getting transplant or autologous CAR-T, with progression-free survival — time before disease worsens or death — as the main goal. SEC
That is why small moves in CRBU can still draw attention. Caribou is trying to move from early data into a late-stage trial, a costly step for a company still far from product revenue.
The balance sheet is part of the story. Caribou had $118.6 million in cash, cash equivalents and marketable securities at March 31, down from $142.8 million at year-end, and said that should fund its current plan into the second half of 2027. The company also said it was exploring ways to fully fund the planned vispa-cel pivotal trial.
A filing showed Caribou sold about 1.08 million shares through its at-the-market program in the first quarter at an average price of $2.11, raising $2.3 million gross. An at-the-market program lets a company sell new shares into the market over time; it can bring in cash, but it can also dilute existing shareholders. Caribou had $93.4 million still available under that program as of March 31.
The competitive backdrop is not soft. Bristol Myers Squibb’s Breyanzi is listed by the FDA as a CD19-directed autologous T-cell therapy for adult large B-cell lymphoma in several settings, while the Yescarta label covers adult large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months, among other uses.
Caribou’s argument is access and speed: an off-the-shelf product could avoid some manufacturing delays tied to patient-specific therapies. But it still has to prove that safety, durability and efficacy can hold up in larger studies.
The risk is plain. If the June follow-up data do not show durability, if regulators or doctors need more evidence, or if Caribou funds late-stage work by selling stock at low prices, the shares could come under pressure again. The company has warned that early or interim clinical data may not predict final results, and that it will remain dependent on financing, partnerships or other capital raises to fund operations and development.
